Analytical Data
-
Gene name
FEV
- Application
-
Alternative Names
ETS-domain transcription factor; FEV (ETS oncogene family); FEV; FEV ETS transcription factor; FEV_HUMAN; Fifth Ewing sarcoma variant; Fifth Ewing variant protein; HSRNAFEV; mPet1; PC12 ETS domain-containing transcription factor 1; PC12 ETS factor 1; Pet-1; Protein FEV
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99581
-
Expression Region
1-238aa
-
AA Sequence
MRQSGASQPLLINMYLPDPVGDGLFKDGKNPSWGPLSPAVQKGSGQIQLWQFLLELLADRANAGCIAWEGGHGEFKLTDPDEVARRWGERKSKPNMNYDKLSRALRYYYDKNIMSKVHGKRYAYRFDFQGLAQACQPPPAHAHAAAAAAAAAAAAQDGALYKLPAGLAPLPFPGLSKLNLMAASAGVAPAGFSYWPGPGPAATAAAATAALYPSPSLQPPPGPFGAVAAASHLGGHYH
-
Molecular Weight
51.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of FEV (Friend of GATA-2) recombinant proteins has gained significant attention in the field of molecular biology and developmental genetics due to FEV's role as a transcription factor involved in hematopoiesis and immune system regulation. Originally identified in the context of T-cell development and function, FEV is part of the GATA family of proteins and plays a crucial role in the differentiation and proliferation of various blood cell lineages. Recent research has focused on the implications of FEV in various pathological conditions, including leukemia and other hematological disorders, highlighting its potential as a therapeutic target. The development of recombinant FEV proteins enables researchers to dissect the molecular mechanisms underlying its function, investigate its interactions with other proteins, and explore its regulatory pathways in normal and disease states. Moreover, recombinant FEV proteins can serve as valuable tools in the study of gene expression, cellular signaling, and the development of targeted therapies. By elucidating the intricate roles of FEV in cellular processes, researchers aim to uncover novel strategies for managing disorders related to blood cell differentiation and function, ultimately contributing to advancements in regenerative medicine and cancer therapy.
